Methicillin-resistant Staphylococcus Aureus Drugs Market is predicted to reach USD 6.49 billion at a CAGR of 5.30% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Methicillin-resistant Staphylococcus Aureus Drugs Market”.

The Methicillin-resistant Staphylococcus Aureus Drugs market is estimated to register a CAGR of 5.30% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Methicillin-resistant Staphylococcus Aureus Drugs market - Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc, AbbVie Inc., Merck & Co Inc, Pfizer Inc, Theravance Biopharma, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Debiopharm International S.A., Nabriva Therapeutics Plc, Melinta Therapeutics Inc, Innovation Pharmaceuticals Inc., and Paratek Pharmaceuticals, Inc

Methicillin-resistant Staphylococcus Aureus Drugs Market Highlights

The global Methicillin-resistant Staphylococcus Aureus Drugs market is accounted to register a CAGR of 5.30% during the forecast period and is estimated to reach USD 6.49 billion by 2032.

One of the main factors propelling the Methicillin-resistant Staphylococcus Aureus Drugs market's expansion is the growing frequency of antibiotic-resistant strains among the general public. The increase in hospital-acquired infections (HAIs) cases worldwide can be blamed for this. More driving the market is the ongoing growth of secondary nosocomial infections brought on by extended hospital stays, which expose healthcare facilities' staff to multidrug-resistant pathogens. Furthermore, an additional factor driving the Methicillin-resistant Staphylococcus Aureus Drugs market is the aging population, which is more prone to contracting MRSA infections. MRSA medication use is also increasing as a result of growing awareness of the various types of bacterial infections. As a result, the market is seeing profitable growth prospects due to a multitude of product advancements, an increase in clinical trials, and the launch of novel drug variations.

Explore In-depth Details: Methicillin-resistant Staphylococcus Aureus Drugs Market Share Report

Segment Analysis

The global Methicillin-resistant Staphylococcus Aureus Drugs market has been segmented into drug class, route of administration, and distribution channel.

On the basis of drug class, the market is segmented into Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, and Other Drug Classes. The lipopeptides segment was attributed to holding the largest market share in 2023 because of the established market for lipopeptides, which includes Daptomycin, and the efficient worldwide distribution that manufacturers and distributors offer.

On the basis of the route of administration, the market is segmented into Oral Administration and Parenteral Administration. The parenteral administration segment was attributed to holding the largest market share in 2023 since it is the quickest way to provide drugs and the first line of therapy. This allows for quick medicine delivery and prompt disease relief for the patient.

Based on distribution channel, the global Methicillin-resistant Staphylococcus Aureus Drugs market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment was expected to hold the largest market share in 2023. The key factors contributing to the hospital pharmacy segment's revenue supremacy globally are the increasing number of multispecialty hospitals and the improved accessibility of generic MRSA drugs in hospital pharmacies across the globe.

Regional Analysis

The global Methicillin-resistant Staphylococcus Aureus Drugs market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Methicillin-resistant Staphylococcus Aureus Drugs market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Methicillin-resistant Staphylococcus Aureus Drugs market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Methicillin-resistant Staphylococcus Aureus Drugs market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for Methicillin-resistant Staphylococcus Aureus Drugs. Because of the strategic location of significant antibiotic manufacturing companies in the United States, North America is expected to maintain its leadership position during the projected period. This is a result of significant players increasing their R&D expenditures for novel drug compounds that combat MRSA infection.

Moreover, the Europe market has been persistently growing over the forecast period because of research grants from both governmental and private corporations in Europe to support the development of anti-MRSA drugs. Furthermore, the UK government is making significant efforts to prevent surgical site infections (SSIs) from occurring in the country. Therefore, the government's increased efforts and preventive measures for the control of surgical site infections are driving market expansion in Europe.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The primary factors for the market expansion are the region's better healthcare system and the rising incidence of MRSA infections. Target market expansion is also expected to be fueled by the government's and public health agency's enhanced help in treating MRSA infections in individuals.

Furthermore, the rest of the world's Methicillin-resistant Staphylococcus Aureus Drugs market is divided into the Middle East, Africa, and Latin America. Due to a growing patient population and the unchecked use of antibiotics, a significant increase is anticipated throughout the rest of the world. Because some bacteria are able to remain and develop a resistance to the antibiotic due to incomplete prescribed antibiotic courses, resistance to antibiotics is constantly increasing.

Key Findings of the Study

• The global Methicillin-resistant Staphylococcus Aureus Drugs market is expected to reach USD 6.49 billion by 2032, at a CAGR of 5.30% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. The improved healthcare system in the area and the growing number of MRSA infections are the main drivers of the market expansion.


• Based on the route of administration, the parenteral administration segment was attributed to holding the largest market in 2023.


• Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., AbbVie Inc., Merck & Co. Inc., Pfizer Inc., Theravance Biopharma, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Debiopharm International S.A., Nabriva Therapeutics Plc, Melinta Therapeutics Inc, Innovation Pharmaceuticals Inc., and Paratek Pharmaceuticals, Inc. are the key market players.